These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

250 related items for PubMed ID: 8732684

  • 1. Activin signaling through activin receptor type II causes the cachexia-like symptoms in inhibin-deficient mice.
    Coerver KA, Woodruff TK, Finegold MJ, Mather J, Bradley A, Matzuk MM.
    Mol Endocrinol; 1996 May; 10(5):534-43. PubMed ID: 8732684
    [Abstract] [Full Text] [Related]

  • 2. Prevention of cachexia-like syndrome development and reduction of tumor progression in inhibin-deficient mice following administration of a chimeric activin receptor type II-murine Fc protein.
    Li Q, Kumar R, Underwood K, O'Connor AE, Loveland KL, Seehra JS, Matzuk MM.
    Mol Hum Reprod; 2007 Sep; 13(9):675-83. PubMed ID: 17704537
    [Abstract] [Full Text] [Related]

  • 3. Follistatin is a modulator of gonadal tumor progression and the activin-induced wasting syndrome in inhibin-deficient mice.
    Cipriano SC, Chen L, Kumar TR, Matzuk MM.
    Endocrinology; 2000 Jul; 141(7):2319-27. PubMed ID: 10875231
    [Abstract] [Full Text] [Related]

  • 4. Characterization of gonadal sex cord-stromal tumor cell lines from inhibin-alpha and p53-deficient mice: the role of activin as an autocrine growth factor.
    Shikone T, Matzuk MM, Perlas E, Finegold MJ, Lewis KA, Vale W, Bradley A, Hsueh AJ.
    Mol Endocrinol; 1994 Aug; 8(8):983-95. PubMed ID: 7997239
    [Abstract] [Full Text] [Related]

  • 5. Stimulation of activin receptor II signaling pathways inhibits differentiation of multiple gastric epithelial lineages.
    Li Q, Karam SM, Coerver KA, Matzuk MM, Gordon JI.
    Mol Endocrinol; 1998 Feb; 12(2):181-92. PubMed ID: 9482661
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Development of cancer cachexia-like syndrome and adrenal tumors in inhibin-deficient mice.
    Matzuk MM, Finegold MJ, Mather JP, Krummen L, Lu H, Bradley A.
    Proc Natl Acad Sci U S A; 1994 Sep 13; 91(19):8817-21. PubMed ID: 8090730
    [Abstract] [Full Text] [Related]

  • 8. Transgenic models to study gonadotropin function: the role of follicle-stimulating hormone in gonadal growth and tumorigenesis.
    Kumar TR, Palapattu G, Wang P, Woodruff TK, Boime I, Byrne MC, Matzuk MM.
    Mol Endocrinol; 1999 Jun 13; 13(6):851-65. PubMed ID: 10379885
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. SMAD3 regulates gonadal tumorigenesis.
    Li Q, Graff JM, O'Connor AE, Loveland KL, Matzuk MM.
    Mol Endocrinol; 2007 Oct 13; 21(10):2472-86. PubMed ID: 17595316
    [Abstract] [Full Text] [Related]

  • 11. Overexpression of activin-beta A subunit mRNA is associated with decreased activin type II receptor mRNA levels in the testes of alpha-inhibin deficient mice.
    Trudeau VL, Matzuk MM, Haché RJ, Renaud LP.
    Biochem Biophys Res Commun; 1994 Aug 30; 203(1):105-12. PubMed ID: 8074643
    [Abstract] [Full Text] [Related]

  • 12. Betaglycan binds inhibin and can mediate functional antagonism of activin signalling.
    Lewis KA, Gray PC, Blount AL, MacConell LA, Wiater E, Bilezikjian LM, Vale W.
    Nature; 2000 Mar 23; 404(6776):411-4. PubMed ID: 10746731
    [Abstract] [Full Text] [Related]

  • 13. Activin and inhibin binding to the soluble extracellular domain of activin receptor II.
    Donaldson CJ, Vaughan JM, Corrigan AZ, Fischer WH, Vale WW.
    Endocrinology; 1999 Apr 23; 140(4):1760-6. PubMed ID: 10098513
    [Abstract] [Full Text] [Related]

  • 14. Genetic evidence that SMAD2 is not required for gonadal tumor development in inhibin-deficient mice.
    Rajanahally S, Agno JE, Nalam RL, Weinstein MB, Loveland KL, Matzuk MM, Li Q.
    Reprod Biol Endocrinol; 2010 Jun 21; 8():69. PubMed ID: 20565978
    [Abstract] [Full Text] [Related]

  • 15. Tissue-specific binding of radiolabeled activin A by activin receptors and follistatin in postimplantation rat and mouse embryos.
    Roberts VJ, Bentley CA, Guo Q, Matzuk MM, Woodruff TK.
    Endocrinology; 1996 Oct 21; 137(10):4201-9. PubMed ID: 8828478
    [Abstract] [Full Text] [Related]

  • 16. The inhibin/activin signalling pathway in human gonadal and adrenal cancers.
    Marino FE, Risbridger G, Gold E.
    Mol Hum Reprod; 2014 Dec 21; 20(12):1223-37. PubMed ID: 25180271
    [Abstract] [Full Text] [Related]

  • 17. Gonadotropins are essential modifier factors for gonadal tumor development in inhibin-deficient mice.
    Kumar TR, Wang Y, Matzuk MM.
    Endocrinology; 1996 Oct 21; 137(10):4210-6. PubMed ID: 8828479
    [Abstract] [Full Text] [Related]

  • 18. Activin-β(c) reduces reproductive tumour progression and abolishes cancer-associated cachexia in inhibin-deficient mice.
    Gold E, Marino FE, Harrison C, Makanji Y, Risbridger G.
    J Pathol; 2013 Mar 21; 229(4):599-607. PubMed ID: 23180294
    [Abstract] [Full Text] [Related]

  • 19. Ovarian regulation of pituitary inhibin subunit and activin receptor type II gene expression: evidence for a nonsteroidal inhibitory substance.
    Dalkin AC, Gilrain JT, Marshall JC.
    Endocrinology; 1994 Sep 21; 135(3):944-9. PubMed ID: 8070390
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.